These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 24192983)

  • 1. Dissolution of the left atrial appendage thrombus with rivaroxaban therapy.
    Takasugi J; Yamagami H; Okata T; Toyoda K; Nagatsuka K
    Cerebrovasc Dis; 2013; 36(4):322-3. PubMed ID: 24192983
    [No Abstract]   [Full Text] [Related]  

  • 2. Stroke and recurrent left atrial appendage thrombus in a patient with atrial fibrillation under old and new oral anticoagulants: a case report.
    Rohla M; Freynhofer MK; Hammerl H; Weiss TW; Huber K
    Thromb Haemost; 2014 Feb; 111(2):375-8. PubMed ID: 24136295
    [No Abstract]   [Full Text] [Related]  

  • 3. Rivaroxaban and other novel anticoagulants for stroke prevention in atrial fibrillation: time to embrace the future.
    Rajappan K
    Heart; 2013 Mar; 99(6):361-2. PubMed ID: 23024007
    [No Abstract]   [Full Text] [Related]  

  • 4. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.
    Aguilar MI; Kuo RS; Freeman WD
    Neurol Clin; 2013 Aug; 31(3):659-75. PubMed ID: 23896498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resolution of giant left atrial appendage thrombus with rivaroxaban.
    Hammerstingl C; Pötzsch B; Nickenig G
    Thromb Haemost; 2013 Apr; 109(4):583-4. PubMed ID: 23348106
    [No Abstract]   [Full Text] [Related]  

  • 8. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.
    Contractor T; Levin V; Martinez MW; Marchlinski FE
    Postgrad Med; 2013 Jan; 125(1):34-44. PubMed ID: 23391669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Rivaroxaban in prevention of stroke in patients with atrial fibrillation].
    Simonyi G; Medvegy M
    Ideggyogy Sz; 2012 Nov; 65(11-12):365-8. PubMed ID: 23289170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban in acute coronary syndromes and atrial fibrillation: rivaroxaban shown to reduce cardiovascular deaths in STEMI patients.
    Aalbers J
    Cardiovasc J Afr; 2012 Oct; 23(9):525-6. PubMed ID: 23108522
    [No Abstract]   [Full Text] [Related]  

  • 11. [Prevention and therapy of thromboembolism: rivaroxaban - better outcome - risk profile as standard therapy].
    MMW Fortschr Med; 2013 Sep; 155(15):56-7. PubMed ID: 24224377
    [No Abstract]   [Full Text] [Related]  

  • 12. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
    Berman JP; Halperin JL
    Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysis of thrombus located in the left atrial appendage. Is it the right time for a Xa factor inhibitor?
    Baran J; Zaborska B; Sikora-Frąc M; Stec S; Kułakowski P
    Kardiol Pol; 2013; 71(11):1210. PubMed ID: 24297727
    [No Abstract]   [Full Text] [Related]  

  • 14. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Summaries for patients. Rivaroxaban in patients transitioned from vitamin K antagonist therapy.
    Ann Intern Med; 2013 Jun; 158(12):I-28. PubMed ID: 23778921
    [No Abstract]   [Full Text] [Related]  

  • 16. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
    J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivaroxaban equals warfarin treatment in atrial fibrillation patients at high risk of stroke.
    Aalbers J
    Cardiovasc J Afr; 2010; 21(6):342-3. PubMed ID: 21135986
    [No Abstract]   [Full Text] [Related]  

  • 18. European Society of Cardiology congress 2011.
    Cardiovasc J Afr; 2011; 22(5):287-8, 291-2. PubMed ID: 21983959
    [No Abstract]   [Full Text] [Related]  

  • 19. Hospital length of stay of nonvalvular atrial fibrillation patients who were administered Rivaroxaban versus Warfarin with and without pretreatment parenteral anticoagulants therapies.
    Laliberté F; Pilon D; Raut MK; Nelson WW; Olson WH; Germain G; Schein JR; Lefebvre P
    Hosp Pract (1995); 2014 Aug; 42(3):17-25. PubMed ID: 25255403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience.
    Mahaffey KW; Hellkamp AS; Patel MR; Hannan KL; Schwabe K; Nessel CC; Berkowitz SD; Halperin JL; Hankey GJ; Becker RC; Piccini JP; Breithardt G; Hacke W; Singer DE; Califf RM; Fox KA
    Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):470-8. PubMed ID: 23759472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.